Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/52795/MonH-2019-174230(v2)
NMA SSA Reference Number: SSA/52795/MonH-2019-183922(v1)
Monash Health Ref: RES-19-0000-368A
Effective start/end date17/07/1916/07/24


  • phase 3 study
  • colorectal cancer
  • treatment efficacy